Bayer’s Legal Gauntlet Meets Analyst Optimism as UBS Sees 38% Upside

Bayer's stock hinges on US class settlement and Supreme Court preemption ruling, while UBS maintains Buy rating with 38% upside potential despite legal uncertainties.

A web of legal deadlines in both the United States and Brazil is pulling Bayer in opposite directions, yet at least one major investment house remains firmly in the bullish camp. The German life-science group faces a pivotal few weeks as two separate court proceedings — one involving a landmark $7.25 billion class settlement, the other a Supreme Court decision on federal preemption — could reshape the trajectory of its multibillion-dollar glyphosate litigation.

UBS analyst Matthew Weston stuck by his “Buy” rating and €52 price target on May 28, implying roughly 38% upside from the current share price of €37.89. His assessment downplays the risk of a glyphosate ban in Brazil, one of Bayer’s most critical markets for the Crop Science division. The bank sees such a prohibition as unlikely, a view that helps remove a major overhang from the stock’s mid-term outlook.

The market, however, has yet to embrace that confidence. The shares dipped 1.4% to €37.57 on Thursday and are still down about 0.5% since the start of the year — a stark contrast to their 53% gain over the past twelve months. The stock has rallied roughly 54% from its 52-week low of €24.64 hit in May 2025, but still sits 23% below the February high of €49.17, underscoring how tightly the price is tied to legal developments.

Two Legal Fronts, One High-Stakes Calendar

On the U.S. side, Bayer’s Monsanto subsidiary proposed a nationwide class settlement in February to resolve current and future non-Hodgkin lymphoma claims linked to Roundup. The financing framework: up to $7.25 billion. A federal judge in St. Louis granted preliminary approval in March, but opposition is mounting fast. U.S. District Judge Vince Chhabria, who oversees thousands of coordinated glyphosate lawsuits, has voiced serious doubts about the legality of the process. Plaintiffs argue that a Missouri court has no authority to bind citizens of other states. The opt-out deadline is June 4, and law firm Weitz & Luxenberg has already pledged to file objections on behalf of around 2,000 clients. The final fairness hearing is set for July 9.

Running parallel to that is a Supreme Court case, Durnell, that asks a fundamental question: does federal law on warning labels for glyphosate supersede state-level requirements? A ruling in Bayer’s favor on the issue of federal preemption could wipe out tens of thousands of claims. The current Supreme Court term ends in June, so a decision could land within weeks.

Chief Executive Bill Anderson has publicly committed to significantly reducing the U.S. litigation burden by the end of 2026. Both cases represent the clearest yardsticks for that pledge.

Operation Metrics: Growth in Ag, Drag from Debt

The underlying business has held its ground. In the first quarter of 2026, Bayer posted revenue of €13.4 billion, up 4.1% on a currency- and portfolio-adjusted basis. EBITDA before special items climbed 9.0% to €4.45 billion. The agriculture segment grew to €7.6 billion, fueled by a licensing agreement in the North American soybean seed business. Earnings per share came in at €2.81, more than double the €1.32 reported a year earlier.

Yet the balance sheet tells a different story. Net financial debt swelled to €32.5 billion at the end of the quarter. Free cash flow sank to negative €2.3 billion, largely due to net outflows of roughly €2 billion for PCB and glyphosate settlements. The company is sticking with its full-year guidance: revenue between €44.5 billion and €46.5 billion, and EBITDA before special items of €9.4 billion to €9.9 billion. Analysts are projecting full-year EPS of €4.37, with a token dividend of €0.11 per share — a reminder that cash is being hoarded for legal costs and debt reduction.

Sector Headwinds Add to the Mix

While the legal story dominates, broader industry trends are also concerning. Germany’s Ifo Institute reported that business expectations in the domestic chemical sector fell to minus 42.0 points in May, the lowest reading since October 2022. The current situation index still stands at minus 17.5, but the plunge in expectations reflects fading demand once linked to geopolitical tensions in the Middle East. High energy costs and stiff Asian competition remain structural drags for Bayer and its peers alike.

Bayer will release its half-year results on August 4. By then, the market should know whether the Supreme Court has tipped the legal scales or whether the Missouri settlement has collapsed under plaintiff opposition. Either outcome is likely to rattle a stock that remains tethered to the courtroom as much as to the field.